摘要:
A kit formulation for the preparation of immunoliposome drug in combined chemotherapy and radionuclide therapy is disclosed, which consists: (1) a vial A containing proteins; (2) a vial B containing Traut's reagent; (3) a vial C containing DSPC, Cholesterol, mPEG-DSPE, Mal-DSPE-PEG and chemotherapy drug; (4) a vial D containing BMEDA, gluconate acetate, SnCl2; (5) a vial E which containing radionuclide solution. The procedure using the kit comprises: (i) withdraw the radionuclide solution from the vial E; (ii) inject the solution into the vial D for enabling reaction; (iii) withdraw the contents of the vial B and inject into the vial A; (iv) withdraw the contents of the protein and Traut's reagent mixtures from the vial A and inject into the vial C for enabling reaction; (v) withdraw the contents of the immunoliposome from the vial C; (vi) inject the immunoliposome into the vial D of step (ii) for enabling reaction.
摘要:
A kit for preparing a radiolabeled liposome is provided, the kit including a liposome suspension and a radionuclide, wherein the liposome suspension includes a conjugate with a structure of [chelator-hydrophilic polymer-lipid]. A method for preparing a radiolabeled liposome using the kit is also disclosed herein, thereby the radiolabeled liposome being produced with the conjugate connected to the surface therein. The advantages of the present disclose such as simple, convenient and without purifying for the produced radiolabeled liposome are thus achieved. Further, the produced radiolabeled liposome has a high specific activity and a high sensitivity and suits for the clinical use.